Clinical Trials Logo

Non-Hodgkin's Lymphoma (NHL) clinical trials

View clinical trials related to Non-Hodgkin's Lymphoma (NHL).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05144347 Terminated - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Start date: April 12, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.

NCT ID: NCT00185679 Terminated - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Haploid Allogeneic Transplant Using the CliniMACS System

Start date: November 2001
Phase: Phase 2
Study type: Interventional

To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.

NCT ID: NCT00089284 Terminated - Clinical trials for Non-Hodgkin's Lymphoma (NHL)

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

Start date: October 28, 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug. This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they work in treating patients with stage II, stage III, or stage IV relapsed or refractory non-Hodgkin's lymphoma.